GlobalData on MSN20h
Interim data success for Salubris Biotherapeutics’ heart failure candidate
The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.
FOX 13 Tampa Bay on MSN9h
New Port Richey man gets heart transplant after setbacks
The BriefPhillip Allen of Newport Richey became the 100th heart transplant recipient, and the first of 2025, at a Largo ...
Le Lézard23h
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will strengthen its leadership and sharpen the Company's focus ...